Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-08

Larimar Therapeutics (LRMR)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,526,423
Carole Ben-Maimon total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
98.01%
Say-on-pay support, latest vote
Companies that benchmark against LRMR
2 companies name LRMR as a compensation peer

Each company listed discloses LRMR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named LRMR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Carole Ben-Maimon$650,000$307,450$660,860$1,889,160$0$0$18,953$3,526,423
President and Chief Executive Officer
Michael Celano505,000173,720291,280709,6840018,2761,697,960
Chief Financial Officer and Secretary
Gopi Shankar466,003160,305167,139483,8390016,0431,293,329
Chief Development Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Carole Ben-Maimon$3,526,423$2,511,649+1,014,774
Michael Celano1,697,9601,384,705+313,255
Gopi Shankar1,293,3291,165,126+128,203

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Frank ThomasDirector2026-05-19A55,150$0$0Derivative, Class A CommonForm 4 ↗
Jeffrey W. ShermanDirector2026-05-19A55,15000Derivative, Class A CommonForm 4 ↗
Thomas E. HamiltonDirector2026-05-19A55,15000Derivative, Class A CommonForm 4 ↗
Joseph TruittDirector2026-05-19A55,15000Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-05-19A55,15000Derivative, Class A CommonForm 4 ↗
Jonathan LeffDirector2026-05-19A55,15000Derivative, Class A CommonForm 4 ↗
Thomas E. HamiltonDirector2026-07-06A50,0003166,890CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Carole Ben-MaimonOPTION$1,889,160
Michael CelanoPRSU291,280
Gopi ShankarPRSU167,139
Carole Ben-MaimonPRSU660,860
Michael CelanoOPTION709,684
Gopi ShankarOPTION483,839
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Carole Ben-Maimon$0$0$1,889,1600.0%
Michael Celano00709,6840.0%
Gopi Shankar00483,8390.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Gopi ShankarOption139,8383.46
Carole Ben-MaimonPSU102,500390,525
Gopi ShankarPSU16,87564,294
Michael CelanoOption2,0842.92
Carole Ben-MaimonOption88,0214.94
Gopi ShankarOption52,5005.88
Michael CelanoPSU23,43789,295
Gopi ShankarOption36,8714.21
Carole Ben-MaimonPSU100,000381,000
Michael CelanoPSU38,000144,780
Michael CelanoPSU50,000190,500
Michael CelanoOption97,6574.21
Carole Ben-MaimonPSU91,000346,710
Carole Ben-MaimonOption206,6414.21
Carole Ben-MaimonOption546,0003.46
Michael CelanoOption205,1113.46
Carole Ben-MaimonOption3,7928.75
Michael CelanoOption32,5004.94
Michael CelanoOption1,6678.75
Carole Ben-MaimonPSU16,53262,987
Gopi ShankarPSU23,30688,796
Michael CelanoPSU34,185130,245
Gopi ShankarPSU25,00095,250
Carole Ben-MaimonOption4,1672.92
05

Incentive-plan design — the Compensation Discussion & Analysis

Consistent with what we believe to be the prevailing market practice for companies in our industry at our stage of development, we have historically used stock options and RSUs to compensate our NEOs in the form of initial new hire grants in connection with the commencement of employment, and thereafter on an annual basis in connection with our annual executive compensation reviews.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1973,822,2371,498,42976,01098.01%Passed
20252025-05-1349,187,1321,445,631172,68897.14%Passed
20242024-05-2948,754,0882,352,496122,89695.4%Passed
20232023-05-0935,507,612337,89555,74199.06%Passed
20222022-05-1013,936,24149,830774,98099.64%Passed
20212021-05-1211,569,53829,7641,12599.74%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1998.01%a
20252025-05-1397.14%b
20242024-05-2995.4%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Joseph TruittIndependent · Board Chair · Audit · Compensation (Chair)$82,500$0$27,400$0$0$109,900
Frank ThomasIndependent · Audit (Chair) · Compensation55,000027,4000082,400
Jonathan LeffIndependent · Compensation · Nominating/Governance (Chair)47,500027,4000074,900
Thomas E. HamiltonIndependent · Audit · Nominating/Governance46,250027,4000073,650
Jeffrey W. Sherman, M.D., FACPIndependent · Nominating/Governance38,750027,4000066,150
Carole S. Ben-Maimon, M.DEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$35,000
Annual equity retainer$27,400
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 7,500
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$270,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$270,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Larimar Therapeutics2025Carole Ben-Maimon$650,000$660,860$1,889,160$0$3,526,423

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Carole Ben-MaimonDEF 14A2026-04-200001193125-26-163942Section “2025 SUMMARY COMPENSATION TABLE” · page 24. As printed: 3,526,423. Filing ↗machine: t90 · r3 · c39 · span 812416–812425
2Section 01, Michael CelanoDEF 14A2026-04-200001193125-26-163942Section “2025 SUMMARY COMPENSATION TABLE” · page 24. As printed: 1,697,960. Filing ↗machine: t90 · r5 · c39 · span 845230–845239
3Section 01, Gopi ShankarDEF 14A2026-04-200001193125-26-163942Section “2025 SUMMARY COMPENSATION TABLE” · page 24. As printed: 1,293,329. Filing ↗machine: t90 · r7 · c39 · span 878057–878066
4Section 03, Carole Ben-Maimon OPTIONDEF 14A2026-04-200001193125-26-163942Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t90 · r3 · c28 · span 808163–808172
5Section 03, Michael Celano PRSUDEF 14ASection “Executive Compensation” · grants of plan-based awards table.
6Section 03, Gopi Shankar PRSUDEF 14A0001193125-26-163942Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
7Section 03, Carole Ben-Maimon PRSUDEF 14A0001193125-26-163942Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
8Section 03, Michael Celano OPTIONDEF 14A2026-04-200001193125-26-163942Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t90 · r5 · c28 · span 840979–840986
9Section 03, Gopi Shankar OPTIONDEF 14A2026-04-200001193125-26-163942Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t90 · r7 · c28 · span 873806–873813
10Section 07, pay ratio10-K2026-03-190001193125-26-115878Section “CEO Pay Ratio”. As printed: —. Filing ↗
11Section 08, Joseph TruittDEF 14A2026-04-200001193125-26-163942Section “Director Compensation”. As printed: 109,900. Filing ↗machine: t73 · r6 · c8 · span 653982–653989
12Section 08, Frank ThomasDEF 14A2026-04-200001193125-26-163942Section “Director Compensation”. As printed: 82,400. Filing ↗machine: t73 · r5 · c8 · span 650017–650023
13Section 08, Jonathan LeffDEF 14A2026-04-200001193125-26-163942Section “Director Compensation”. As printed: 74,900. Filing ↗machine: t73 · r4 · c8 · span 646053–646059
14Section 08, Thomas E. HamiltonDEF 14A2026-04-200001193125-26-163942Section “Director Compensation”. As printed: 73,650. Filing ↗machine: t73 · r3 · c8 · span 642088–642094
15Section 08, Jeffrey W. Sherman, M.D., FACPDEF 14A2026-04-200001193125-26-163942Section “Director Compensation”. As printed: 66,150. Filing ↗machine: t73 · r7 · c8 · span 657965–657971
16Section 08, Carole S. Ben-Maimon, M.DDEF 14A2026-04-200001193125-26-163942Section “Director Compensation”. As printed: 0. Filing ↗
17Section 02, Frank Thomas 2026-05-19Form 42026-05-200001193125-26-232657Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Jeffrey W. Sherman 2026-05-19Form 42026-05-200001193125-26-232705Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Thomas E. Hamilton 2026-05-19Form 42026-05-200001193125-26-232644Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Joseph Truitt 2026-05-19Form 42026-05-200001193125-26-232667Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, James E. Flynn 2026-05-19Form 42026-05-200001193805-26-000669Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Jonathan Leff 2026-05-19Form 42026-05-200001193125-26-232933Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Thomas E. Hamilton 2026-07-06Form 42026-07-080001193125-26-298523Insider equity transaction reported since the proxy statement. Filing ↗
24Section 06, 2026 voteForm 8-K2026-05-190001193125-26-230852Item 5.07 · say-on-pay result. As reported: 98.01% (votes for as printed: 73,822,237). Filing ↗
25Section 06, 2025 voteForm 8-K2025-05-130000950170-25-070287Item 5.07 · say-on-pay result. As reported: 97.14% (votes for as printed: 49,187,132). Filing ↗
26Section 06, 2024 voteForm 8-K2024-05-310000950170-24-067306Item 5.07 · say-on-pay result. As reported: 95.4% (votes for as printed: 48,754,088). Filing ↗
27Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
28Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
29Section 09b board cost (computed)ComputedcomputedCash 270,000 + equity 0 + all other 0 = 270,000, summed across the director compensation table rows.machine: formula: Σ = 270,000
30Larimar Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-200001193125-26-163942CEO total compensation as printed in Larimar Therapeutics's own proxy. As printed: 3,526,423. Filing ↗machine: t90 · r3 · c39 · span 812416–812425